TITLE

NEW FORMULATIONS

PUB. DATE
July 2007
SOURCE
Drug Topics;7/9/2007, Vol. 151 Issue 13, p42
SOURCE TYPE
Trade Publication
DOC. TYPE
Product Review
ABSTRACT
The article evaluates drugs, including the FazaClo Orally Disintegrating Tablets clozapine from Avanir Pharmaceuticals and Zyflo CR Extended-Release Tablets zileuton from Critical Therapeutics.
ACCESSION #
25886323

 

Related Articles

  • Avanir prepares for sale. Niiler, Eric // Nature Biotechnology;Nov99, Vol. 17 Issue 11, p1049 

    Reports on the possibility of sale of San Diego, California-based company Avanir Pharmaceuticals Inc. Reason behind this possibility; Effect of inefficiency of the company's chief executive officer David Katz on financial conditions of the company.

  • Financings Roundup.  // BioWorld Today;8/8/2007, Vol. 18 Issue 153, p6 

    The article reports on the completion of a $48 million private placement by Azur Pharma Ltd. representing 28 percent of its outstanding shares. The privately held company completed its $42 million-plus acquisition of the marketed antipsychotic drug FazaClo (clozapine) from Avanir Pharmaceuticals...

  • OTHER NEWS TO NOTE.  // BioWorld Today;6/1/2007, Vol. 18 Issue 106, p2 

    The article offers news briefs on biotechnology. Avanir Pharmaceuticals Inc., has received U.S. Food and Drug Administration (FDA) approval for a new formulation of its curently marketed antipsychotic drug FazaClo (clozapine). Macroflux Corp., has named Cory Zwerling president and chief...

  • Avanir Raising $88M To Market New Drug. Lyster, Michael // Orange County Business Journal;11/22/2010, Vol. 33 Issue 47, p4 

    The article reports on the plans of Aliso Viejo-based drug maker Avanir Pharmaceuticals Inc. to sell 23 million shares of its stocks at 4.40 dollars apiece to raise 88 million dollars to market its newly approved drug Nuedexta in California.

  • Avanir Seeks Approval for Nuedexta Sales in Europe. Reed, Vita // Orange County Business Journal;11/7/2011, Vol. 34 Issue 45, p6 

    The article reports on the application of Avanir Pharmaceuticals Inc. for European regulatory approval for the sale of its drug Nuedexta.

  • Avanir Seeks Approvals to Use Core Drug for MS Pain. Reed, Vita // Orange County Business Journal;5/2/2011, Vol. 34 Issue 18, p56 

    The article reports that Avanir Pharmaceuticals Inc. is searching for approval for its AVP-923 drug to treat central neuropathic pain in patients with multiple sclerosis.

  • Wall Street Shows Concerns, Patience on Avanir's New Drug. Reed, Vita // Orange County Business Journal;5/16/2011, Vol. 34 Issue 20, p9 

    The article reports on a 14.5 million dollars net loss for the Aliso Viejo-based drug maker Avanir Pharmaceuticals Inc. for concerns on the performance of its core drug, Nuedexta in California.

  • Avanir's Stock Soars on Word of Potential Anthrax Drug. Webb, Marion // San Diego Business Journal;2/17/2003, Vol. 24 Issue 7, p9 

    Reports on the increase in the shares of Avanir Pharmaceuticals Inc. in San Diego, California. Factors contributing to the rise in the shares of the companies; Development of antibiotics for treating anthrax; Release of the first quarter earnings of Avanir.

  • AVANIR PHARMACEUTICALS.  // San Diego Business Journal;1/5/2004, Vol. 25 Issue 1, p19 

    Presents an overview of Avanir Pharmaceuticals, a biopharmaceutical drug discovery and development company engaged in research, development, commercialization, licensing, and sales of drugs. Stock values; Performance record; Corporate directors.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics